Azitra Inc (AZTR) News

AZTR under $2

What's the news on the street today... "notice of effectiveness"

AZTR new 52 week low

AZTR TO 34C

cheap

Has further to fall......

ready

CEO purchased shares on the offering at .30, not many do that

https://stockcharts.com/h-sc/ui?s=aztr&p=W&yr=1&mn=6&dy=0&id=p24986097784&listNum=23&a=1113701411

https://stockcharts.com/h-sc/ui?s=aztr&p=W&yr=1&mn=6&dy=0&id=p24986097784&listNum=23&a=1113701411

double bottom from .16

https://stockcharts.com/h-sc/ui?s=aztr&p=30&yr=0&mn=0&dy=15&id=p24986097784&listNum=23&a=1113701411

slowly but surely

strange pos indeed

I find it strange too release such good
News on a Friday, rather than Monday, unless more is expected, it’s obviously Friday is always a pull out day.

Enjoy your day

bs day friday worth to watch

https://stockcharts.com/h-sc/ui?s=aztr&p=D&yr=0&mn=5&dy=10&id=p24986097784&listNum=23&a=1113701411

nice

Imagine waking up one day and this one is trading at 2-$4 per share due to some buyout or pharma deal, or sale of intellectual property like patents/ research etc or FDA Approval and hellllo 100s of millions of gain to market cap lol

I'd keep an eye on this one. Conducting a few presentations in May regarding their be data... could be ripe for some liquidity events IE Buyout or pharma deals

28M O/S 3M float. The company has 12.5 months of cash left based on quarterly cash burn of -$1.59M and estimated current cash of $6.6M (https://dilutiontracker.com/app/search/AZTR).

Trash

Interesting ticker

AZTR..............................https://stockcharts.com/h-sc/ui?s=AZTR&p=W&b=5&g=0&id=p86431144783

Azitra Inc NYSE American: AZTR

GoSymbol lookup
Health Care : Biotechnology | Company profile
Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library comprised of approximately 1,500 bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease.